Unraveling resistance mechanisms to the novel nucleoside analog RX-3117 in lung cancer: insights into DNA repair, cell cycle dysregulation and targeting PKMYT1 for improved therapy
Mahrou Vahabi(Amsterdam Neuroscience), Elisa Giovannetti(University of Pisa)
Cited by 1
Related Papers
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
|Drug Resistance Updates|2019|198
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
|Expert Opinion on Investigational Drugs|2015|153
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
|npj Precision Oncology|2023|146
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon
|Advances in experimental medicine and biology|2017|143
Small cell lung cancer: Novel treatments beyond immunotherapy
|Seminars in Cancer Biology|2022|98